StocksMedium•25 September 2026•
1 min read
Merck and Daiichi Sankyo Withdraw Lung Cancer Drug Application
Key Facts
1Daiichi Sankyo and Merck have voluntarily withdrawn the Biologics License Application for ifinatamab deruxtecan.
2The application sought accelerated approval for adult patients with extensive-stage small cell lung cancer.
Daiichi Sankyo and Merck have voluntarily withdrawn the Biologics License Application for ifinatamab deruxtecan. Business Wire reported that the application sought accelerated approval for adult patients with extensive-stage small cell lung cancer.
The decision to withdraw the application followed discussions with regulatory authorities regarding the drug candidate. In equity markets, MRK closed at $148.01 on September 24, 2026, while DSNKY closed at $18.28 on the same date.